Triastek Archives

News and Trends 25 Jul 2023

Triastek sees positive results from printed oral treatment for ulcerative colitis

Triastek, Inc. has completed its first in human study of its third 3D printing drug product, T21, designed to treat moderate to severe ulcerative colitis (UC). Imaging results from the study confirmed that T21 tablets are precisely delivered and released to the target site – the colon – for the drug release. The administration of […]

July 25, 2023 - 3 minutesmins - By Jim Cornall

More News! 18 Nov 2022

Triastek cleared for 3D printed medicine treatment of ulcerative colitis

Triastek, Inc. has received clearance for its Investigational New Drug (IND) application from the United States Food and Drug Administration (FDA) to initiate clinical studies of the 3D printed medicine, T21, a potential treatment for ulcerative colitis. “We are excited to receive IND clearance to begin clinical trials of this potentially transformative treatment for patients,” […]

November 18, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 19 Aug 2022

Beyond Biotech podcast 10: Endpoint Health, Nevrargenics, Triastek

This week our guests on the podcast are Xianghao Zuo, deputy director of R&D at Triastek; Endpoint Health CEO Jason Springs; and Andy Whiting, CEO of Nevrargenics. Triastek and Lilly working together on 3D printing for drugs A new research collaboration between Chinese company Triastek, Inc. and Eli Lilly and Company will leverage 3D printing […]

August 19, 2022 - 3 minutesmins - By Jim Cornall

Best in Biotech 28 Jul 2022

Five companies personalizing treatments with 3D printed drugs

There has been a noticeable shift in recent years towards the personalization of medicine, with the pharmaceutical industry showing interest in pills that are tailored to a patient’s needs. Here are five companies that are leveraging 3D printing to produce customizable drugs. Conventional drug production relies on large-scale batch manufacturing, which is very efficient at […]

July 28, 2022 - 5 minutesmins - By Omnia Ibrahim

News and Trends 15 Jul 2022

Triastek forms pact with Eli Lilly to 3D print tablets for oral drug delivery

A new research collaboration between Triastek, Inc. and Eli Lilly and Company will leverage 3D printing technology to achieve precise targeting and programmed drug release in the intestine. The China-based Triastek has developed proprietary 3D printing technology that provides solutions for drug development. According to the agreement, Triastek and Lilly will focus on improving the […]

July 15, 2022 - 3 minutesmins - By Omnia Ibrahim

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us